Amicus Therapeutics for a better world

Amicus Therapeutics is a biopharmaceutical company founded on February 4th, 2002 in Cranbury, New Jersey. They focus on rare diseases with the help of Chaperone-Advanced Replacement Therapy platform and enzyme replacement therapies. They deal with genetic disorders, such as Epidermolysis Bullosa (EB). They also have the technology to take on Lysosomal Storage Disorders Fabry disease and Pompe disease. The public company has an employee range of 201-500 devoted workers.

 

The company is very active in developing new drug applications, which shows their professionalism and loyalty to withholding a high standard in their research (DialDish). In July of 2017, Amicus Therapeutics announced their new drug application for the oral precision medicine migalastat for Fabry disease. They are also currently active in a study for Pompe disease. It is a clinical study to develop a better treatment for Pompe disease victims. Developments like these changes the lives of people struggling with these disorders in a significant way.

 

It becomes clear that this pharmaceutical company works not only for the research of new solutions and technological development to treat rare diseases but also for the training and inspiring of specialists. This is a great precedent for a big company like Amicus Therapeutics.

 

Amicus Therapeutics’ devotion has won them many awards and recognitions, such as the naming of their Chairman and CEO, John F. Crowley, to the 2017 PharmaVOICE 100 List (https://seekingalpha.com/article/4073303-amicus-therapeutics-small-biotech-seems-big-mo). This is a list created to recognize the most inspiring and innovative figures in the life-sciences industry. While this is very good for the image of the company, it is not their only achievement. The company organizes annual intern program for the young and inexperienced. They earn experience directly from employees of Amicus Therapeutics.

 

Another praiseworthy activity is their three-day volunteering effort for Habitat for Humanity. While this has nothing to do with the medical field, it has everything to do with a company being more than just a corporation that wins money through an activity. This is about bringing good into the world by caring for people in all circumstances.

More about Amicus Therapeutics on Twitter | Crunchbase